VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA

BACKGROUND: We investigated the safety and efficacy of bevacizumab combined with gemcitabine followed by infusional 5-fluorouracil (5-FU) in patients with advanced pancreas cancer (APCA). DESIGN: Patients with untreated APCA received bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2) over 100 min, and 5...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Martin, L. K., Li, X., Kleiber, B., Ellison, E. C., Bloomston, M., Zalupski, M., Bekaii-Saab, T. S.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2012
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841413/
https://ncbi.nlm.nih.gov/pubmed/22767582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds134
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars